ACACIA RESEARCH CORPORATION

FOR RELEASE
July 16, 2003

COURT ISSUES INJUNCTIONS AGAINST ADULT WEBMASTERS AND CONTENT PROVIDERS FOR VIOLATING ACACIA'S PATENTS

Newport Beach, Calif. – (BUSINESS WIRE) July 16, 2003 – Acacia Research Corporation (Nasdaq: ACTG; CBMX) announced today that the United States District Court for the Central District of California has issued injunctions, resulting from Default Judgments, against five (5) Adult Entertainment companies for violating Acacia's DMT patents. The Court issued the injunctions against Extreme Productions, Go Entertainment, Lace Productions, WebZotic LLC, and Wild Ventures, LLC. The injunctions prohibit these companies from infringing Acacia's DMT patents by transmitting compressed digital video information from any of their websites.

Acacia also recently entered into License and Settlement Agreements with adult content providers Babenet Ltd. and White Sands Communications Inc., bringing the total number of licensees of Acacia's DMT technology to twenty seven (27).

Acacia's DMT technology, which is covered by pioneering patents, relates to audio and video transmission and receiving systems, commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable television, and wireless systems.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group.

The Acacia Technologies group licenses its DMT and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA synthesis/diagnostics, drug discovery, and immunochemical detection. CombiMatrix's Express Track[sm] drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: